A study on transcatheter aortic valve replacement (TAVR) without prior balloon aortic valvuloplasty (BAV) using the SAPIEN 3 device assessed long-term outcomes. Results from the DIRECTAVI trial revealed no significant difference in heart valve dysfunction (HVD) incidence between direct TAVR and BAV groups over a median 3.8-year follow-up. Prevalence of prosthesis-patient mismatch was low and comparable. Major outcomes like death, stroke, heart failure hospitalization, and pacemaker implantation showed no significant variation between the groups. The findings support the safety and feasibility of direct TAVR, suggesting its wider application.
Like
Save
Share